The impact of non-dysentery Shigella-associated diarrhea in children
The impact of non-dysentery Shigella-associated diarrhea in children
批准号:
10209109
负责人:
Subhra Chakraborty
金额:
$40.68万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
未结题
起止时间:
2021-03-09 至 2026-02-28
关键词:
AddressAgeAlgorithmsAnthropometryAntibiotic TherapyAntibioticsBangladeshBiological AssayBirthBloodBlood specimenCase-Control StudiesChildChild DevelopmentChild HealthChronicClinicalCognitiveCohort StudiesCollaborationsCountryDetectionDevelopmentDiagnosticDiagnostic testsDiarrheaDysenteryEnrollmentFecesFunctional disorderFutureGene ExpressionGuidelinesHome visitationHospitalizationHospitalsHydration statusImpairmentIndiaInfectionInflammationInflammatoryInvadedKineticsLaboratoriesLengthLifeLiteratureMalnutritionMorbidity - disease rateMucous MembraneNatureNutritional statusPatientsPerformancePeruPoverty AreasProxyPublishingRapid diagnosticsRecommendationResearchRiskRuralRural HospitalsSamplingSavingsShigellaShigella InfectionsSymptomsTestingWorld Health OrganizationZambiacare seekingcognitive developmentcostdiagnostic assayevidence basefield studyfitnessgut healthimprovedindexinginflammatory disease of the intestineintestinal epitheliummortalitymortality risknovelnutritionprospectiverapid testrecruitrural settingstandard carestool samplesystemic inflammatory responsetreatment guidelines
中文摘要
项目总结/摘要
志贺氏菌是世界贫困地区儿童中度至重度腹泻的主要原因。
志贺氏菌以引起痢疾(便血)而闻名。然而,大多数感染志贺氏菌的儿童
出现水样腹泻。目前世界卫生组织(WHO)的治疗指南
志贺氏菌病(在缺乏快速、敏感、简单和廉价的诊断测试的情况下)
当粪便中出现可见的血液时使用抗生素。因此,非痢疾志贺氏菌相关性腹泻
(NDSD)病例不会使用抗生素治疗。没有痢疾可能并不意味着死亡风险低
并且不排除志贺氏菌是腹泻的原因。特别脆弱的年幼儿童或
营养不良,志贺氏菌感染的识别和治疗可能会挽救生命。可以假设,
NDSD病例,如果迅速发现,应使用抗生素治疗,以提高生存率和长期
儿童的发展潜力。此类病例的识别将需要快速检测来记录这些
感染,以便能够及时启动治疗,并以证据为基础。
为了解决这些问题,我们建议进行一项前瞻性纵向病例对照研究,
NDSD的病理生理学和NDSD对儿童的影响与痢疾志贺氏菌病相比。的
在孟加拉国医院寻求治疗的腹泻儿童(痢疾和NDSD),
志贺氏菌和志贺氏菌阴性水样腹泻的第三组将入组并进行前瞻性随访。我们
研究的具体目标如下:
AIM 1.确定与NDSD病例相关的住院发病率和风险及其对营养的影响
儿童的地位和认知发展。
AIM 2.了解NDSD对儿童肠道屏障功能、全身和肠道炎症的影响。
AIM 3.评价简单快速检测S-RLDT是否适用于病例检测和治疗
志贺菌病流行国家农村医院临床环境中的志贺菌病
总的来说,我们提出的研究将通过了解
NDSD和NDSD对儿童健康的影响。这项研究将有助于了解是否有必要改变
为了更好的儿童生存和发展,目前的志贺氏菌病治疗指南。本研究还将
验证一种能够识别将从抗生素中受益的患者的快速测试。
英文摘要
PROJECT SUMMARY / ABSTRACT
Shigella is a primary cause of moderate-to-severe diarrhea in children living in impoverished areas of the world.
Shigella is known for causing dysentery (blood in stool). However, majority of the children infected with Shigella
present with watery diarrhea. The current World Health Organization (WHO) guidelines for treatment of
shigellosis (in the absence of a rapid, sensitive, simple and inexpensive diagnostic test) recommends treatment
with antibiotics when presence of visible blood in stool. Thus, the non-dysentery Shigella associated diarrhea
(NDSD) cases would not be treated with antibiotics. Absence of dysentery may not indicate a low risk of death
and does not exclude Shigella as a cause of diarrhea. In particularly vulnerable younger children or with
malnutrition, identification and treatment of Shigella infection might be life-saving. It may be hypothesized that
NDSD cases, if identified quickly, should be treated with antibiotics to improve survival and long-term
developmental potential in children. Identification of such cases will require a rapid test to document these
infections so that treatment can be initiated promptly, and evidence based.
To address these questions, we propose to conduct a prospective longitudinal case control study to understand
the pathophysiology of NDSD and the impact of NDSD in children compared to dysentery shigellosis. The
children seeking care in the hospital in Bangladesh with diarrhea (both dysentery and NDSD), that is positive for
Shigella and a third group with Shigella negative watery diarrhea will be enrolled and prospectively followed. Our
study has the following specific aims:
AIM 1. Determine morbidity and risk of hospitalization associated with NDSD cases and its impact on nutritional
status and cognitive development of the children.
AIM 2. Understand the impact of NDSD on gut barrier function, systemic and gut inflammation in children.
AIM 3. Evaluate if the simple and rapid test S-RLDT could be applicable for case detection and treatment of
shigellosis in the clinical settings of the rural hospitals of the endemic countries.
Collectively, our proposed research would broadly impact the field by understanding the pathophysiology of
NDSD and the impact of NDSD in child health. This study will help to understand if there is a need to change the
current guidelines of shigellosis treatment for better survival and development of the children. This study will also
validate a rapid test capable of identifying the patients who will benefit from antibiotics.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
The impact of non-dysentery Shigella-associated diarrhea in children
-
批准号:10368152
-
项目类别:
-
资助金额:$66.13万
-
财政年份:2021
-
负责人:Subhra Chakraborty
-
依托单位:
The impact of non-dysentery Shigella-associated diarrhea in children
-
批准号:10588251
-
项目类别:
-
资助金额:$66.59万
-
财政年份:2021
-
负责人:Subhra Chakraborty
-
依托单位:
The impact of non-dysentery Shigella-associated diarrhea in children
-
批准号:10247203
-
项目类别:
-
资助金额:$52.4万
-
财政年份:2020
-
负责人:Subhra Chakraborty
-
依托单位:
A novel diagnostic tool to aid vaccine evaluation and surveillance of enterotoxigenic E. coli and Shigella
-
批准号:9751198
-
项目类别:
-
资助金额:$16.38万
-
财政年份:2018
-
负责人:Subhra Chakraborty
-
依托单位:
Natural infection of norovirus and sapovirus in a birth cohort in a Peruvian periurban community
-
批准号:9239284
-
项目类别:
-
资助金额:$38.47万
-
财政年份:2015
-
负责人:Subhra Chakraborty
-
依托单位:
Natural infection of norovirus and sapovirus in a birth cohort in a Peruvian periurban community
-
批准号:9091429
-
项目类别:
-
资助金额:$64.15万
-
财政年份:2015
-
负责人:Subhra Chakraborty
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: